Professor Ioanna Gouni-Berthold, University of Cologne, Germany
After many years working with lipid-lowering drugs during their development, I am very happy that clinical trials are underway of multiple agents targeting Lp(a) – a protein which I have always found fascinating and which is at least six times more pro-atherogenic per particle than LDL. The novel agents that are now in development fall into three categories – antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs) and small molecules.
